Filing status
- Accounts due
- 30 November 2026
- Last accounts
- 28 February 2025
- Conf. stmt due
- 10 March 2027
- Last conf. stmt
- 24 February 2026
Adorx Therapeutics Limited
- Incorporated
- 24 February 2017 (9 years)
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Kyparissia Katie Sirinakis
- Accounts type
- Full
- Region
- Scotland
- Address
- 137A George StreetEdinburghEH2 4JY
Charges
- Total
- 1
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 1
Officers 3 active
Officer details are public data from the Companies House register.
Sirinakis, Kyparissia Katie
Director · Appointed 21 February 2023
American
Born June 1965 (61)
Director · Appointed 9 March 2018
British
Born February 1962 (64)
Director · Appointed 24 February 2017
British
Born July 1967 (59)
Officer history (1 former)
21 February 2023
Appointed Sirinakis, Kyparissia Katie as Director
21 February 2023
Resigned Roper, Elizabeth Ann as Director
9 March 2018
24 February 2017
24 February 2017
Appointed Roper, Elizabeth Ann as Director
Ownership 2 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 9 March 2018
Owns 25–50% of shares
Holds 25–50% of voting rights
Private Limited Company
Reg. no. 07933818
Corporate entity · Notified 24 February 2017
Owns 50–75% of shares
Holds 50–75% of voting rights
Right to appoint and remove directors
Private Limited Company
Reg. no. Sc437985
Group structure 20 companies
Ownership group derived from the Companies House PSC register
Eif Co-Invest LP Has significant influence or control
Epidarex Capital II, LP Has significant influence or control
Edinburgh Molecular Imaging Limited Owns 25–50% of shares
Epidarex Capital Iii UK, LP Has significant influence or control
Epidarex Exeed Limited Owns 75–100% of shares
Lario Therapeutics Limited Owns 50–75% of shares
Macomics Ltd Owns 25–50% of shares
Rinn Therapeutics Limited Owns 75–100% of shares
Epidarex Capital IV, LP Has significant influence or control
Epidarex Capital Partners Limited Owns 75–100% of shares
Adorx Therapeutics Limited This company Owns 50–75% of shares
Clyde Biosciences Limited Owns 50–75% of shares
Epidarex Capital II GP, LP Part right to 75–100% of surplus assets
Epidarex Capital Iii UK GP, LP Part right to 75–100% of surplus assets
Epidarex Capital UK GP, LLP Holds 25–50% of voting rights
Epx II Co-Invest LP Right to appoint and remove a person
Epidarex Partners Limited Owns 75–100% of shares
Filings 50
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 24 April 2026 | Confirmation statement with updates | 24 February 2026 | ||
| 28 November 2025 | Full accounts | 28 February 2025 | ||
| 24 February 2025 | Confirmation statement with updates | 24 February 2025 | ||
| 24 September 2024 | Full accounts | 28 February 2024 | ||
| 20 March 2024 | Confirmation statement with updates | 24 February 2024 |
Some other companies at this address
Other companies in this industry
Edinburgh
Cambridge
Cambridge
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →